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Introduction
The somatic JAK2V617F mutation has been detected in ~95% patients with polycythemia vera (PV) and 50-60% patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF) [1] [2] [3] [4] [5] . Retroviral bone marrow transplantation, transgenic and knock-in mice models of Jak2V617F have shown that Jak2V617F is directly responsible and sufficient to cause PV [6] [7] [8] [9] [10] [11] , and may contribute to the pathogenesis of ET and PMF 7, 8, 12 . Expression of Jak2V617F resulted in marked expansion of erythroid progenitors and Epo-independent erythroid colonies in the bone marrow and spleens of Jak2V617F knock-in mice [9] [10] [11] . A previous study indicated that the JAK2V617F mutation has an inherent capacity to skew differentiation of PV hematopoietic stem cells (HSC) towards the erythroid lineage 13 . Dupont et al., showed that the JAK2V617F mutation triggered
Epo hypersentivity and erythroid amplification in PV hematopoietic progenitors 14 .
Moreover, enforced expression of JAK2V617F in human cord blood hematopoietic progenitors resulted in enhanced erythroid colony formation 15 . Although these studies suggested a direct link between expression of JAK2V617F and expansion of erythroid progenitors, it was not clear whether expression of JAK2V617F confers leukemia stem cell (LSC)-like properties to erythroid progenitors. In this study, we specifically expressed Jak2V617F in erythroid progenitors using EpoRCre mouse and determined the effects of erythroid-lineage restricted expression of Jak2V617F in vivo.
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Design and Methods
Mice
Conditional Jak2V617F knock-in 9 , EpoRCre 16 and MxCre 17 mice were previously described. The Jak2V617F knock-in mouse was crossed to the EpoRCre mouse to generate EpoRCre;V617F/+ (heterozygous Jak2V617F) and EpoRCre;V617F/V617F
(homozygous Jak2V617F) mice. The MxCre;V617F/+ mouse was generated as described previously 9 . Mice with C57BL/6 x 129Sv mixed background were used for all experiments except for transplantation into secondary recipients, in which MxCre;V617F/+ or EpoRCre;V617F/V617F mice were backcrossed to C57BL/6 background for 7 generations. All animal studies were approved by the Committee for the Humane Use of Animals of SUNY Upstate Medical University.
Secondary transplantation
The 
Statistical analysis.
Results are expressed as mean ± SEM, and data were analyzed by the two-tailed Student's t-test. P <0.05 was considered to be statistically significant.
Results and Discussion
The Conditional Jak2V617F knock-in mouse 9 was crossed with the EpoRCre mouse, which had been shown to cause erythroid lineage-restricted expression of Cre recombinase and efficient recombination of floxed alleles in erythroid progenitors 16, 18 .
To verify the EpoRCre-mediated expression of Jak2V617F in the hematopoietic Peripheral blood smears also showed increased RBC and reticulocytes in mice expressing Jak2V617F, with greater increase in homozygous compared to heterozygous mice ( Figure 1F ). Polycythemia was accompanied by significant increase in spleen size in mice expressing both heterozygous and homozygous Jak2V617F, although homozygous 7 Jak2V617F expression in erythroid progenitors resulted in much larger spleen size compared to heterozygous Jak2V617F ( Figure 1G ). Thus, Jak2V617F expression in erythroid progenitors induced extramedullary hematopoiesis in mice. Together, these results suggest that erythroid-lineage restricted expression of Jak2V617F induces a myeloproliferative neoplasm (MPN) in mice.
Flow cytometric analysis of the BM and spleen from mice expressing Jak2V617F showed significant increases in CD71 + Ter119 + erythroid progenitors compared with control mice (Figure 2A-B) . Expansion of the CD71 + Ter119 + population was greater in the spleen than in the BM of Jak2V617F-expressing mice compared with control animals (Figure 2A-B) . Moreover, homozygous Jak2V617F expression resulted in significantly greater increases in the CD71 + Ter119 + population in the BM and spleens compared with heterozygous Jak2V617F expression (Figure 2A-B) . However, erythroid-restricted expression of either heterozygous or homozygous Jak2V617F did not cause significant increase in myeloid (Gr-1/Mac-1) or megakaryocytic (CD41/CD61) precursors compared with controls (Figure 2A-B) . Therefore, the splenomegaly observed upon EpoRCremediated expression of Jak2V617F in these animals was mainly due to the expansion of erythroid lineage cells.
Histopathologic analyses also showed expansion of erythroid precursors in the spleens of EpoRCre;V617F/+ and EpoRCre;V617F/V617F mice (24-28 weeks old) compared with control animals (Supplemental Figure S2 , left panels). Reticulin staining indicated the absence of fibrosis in the spleens of these animals (Supplemental Figure S2 , right panels). In contrast, MxCre-mediated expression of Jak2V617F in all hematopoietic compartments induced trilineage hyperplasia (expansion of megakaryocytes, erythrocytes 8 and myeloid cells) and fibrosis in the spleens (Supplemental Figure S2) , as we previously observed 9 .
Erythroid-lineage restricted expression of Jak2V617F also resulted in a marked increase in BFU-E and CFU-E colonies in the BM and spleens in the presence or absence of Epo (Figure 2C-D) . Expression of homozygous Jak2V617F, however, resulted in a significantly larger number of BFU-E and CFU-E colonies in the BM and spleens compared with heterozygous Jak2V617F (Figure 2C-D) . The presence of a larger number of Epo-independent CFU-E colonies in the BM and spleens of Jak2V617F mice ( Figure   2D ) suggested that erythroid progenitors were efficiently transformed by Jak2V617F
expression. Together, these data establish that erythroid-specific expression of Jak2V617F is sufficient to transform erythroid progenitors and induce MPN in mice.
Although HSCs are frequent targets of transformation in leukemogenesis and have the capacity to initiate the disease 19, 20 , several recent studies suggest that more mature progenitor cells, which normally lack any potential for self-renewal, could also be an origin of LSC [21] [22] [23] . The oncogenic mutations may confer self-renewal properties to committed progenitors in some myeloid malignancies [21] [22] [23] . We showed previously that the MxCre-mediated expression of Jak2V617F in all hematopoietic compartments resulted in a PV-like disease associated with a marked increase in MEP and erythroid progenitors 9 . We also showed that the MPN disease in MxCre;V617F/+ mice could be transplanted into secondary recipients 9 . To determine whether Jak2V617F expression confers LSC-like properties to committed progenitors (MEP or GMP) or erythroid progenitors, we performed transplantation experiments. We sorted LSK, MEP and GMP from the BM of diseased MxCre;V617F/+ mice, and early erythroid progenitors (c- In this report, we demonstrate for the first time that expression of Jak2V617F in erythroid progenitors is sufficient to induce MPN-like disease in mice. Whereas heterozygous Jak2V617F expression in erythroid progenitors resulted in a mild form of MPN, homozygous Jak2V617F expression caused significant increase in hematocrit, hemoglobin and RBC counts associated with marked expansion of erythroid progenitors in the BM and spleens, and transformation of erythroid progenitors characterized by large numbers of Epo-independent CFU-E colonies (Figures 1 and 2 ). These results suggest that Jak2V617F homozygosity enhances erythroid expansion and renders erythroid progenitors more Epo-independent. These findings are consistent with the earlier observation that most homozygous JAK2V617F erythroid progenitors in human PV patients were Epo-independent and more sensitive to Epo compared to heterozyzygous JAK2V617F erythroid progenitors 14 . Notably, the phenotypes observed upon erythroid lineage-restricted expression of Jak2V617F in mice were less strong than those observed with MxCre-mediated expression of Jak2V617F in all hematopoietic compartments including HSC 9 . We and other investigators have observed that Jak2V617F-expressing HSCs are capable of initiating and transferring the MPN in secondary and tertiary recipients ( Figure 3 
